F10 and atrial fibrillation: The ROCKET-AF study included more than 14.000 patients with atrial fibrillation and demonstrated a noninferiority of the factor Xa inhibitor rivaroxaban compared to warfarin for the prevention of stroke or systemic embolism [25].